XML 272 R215.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of geographical areas [line items]        
Net sales € 41,081 € 37,817 [1] € 37,651 [1]  
Biopharma (operating segment)        
Disclosure of geographical areas [line items]        
Net sales 41,081 37,817 [2],[3] 37,651 [3],[4],[5]  
Disclosure of operating segments [line items]        
Business operating income 11,285 11,155 [2] 12,764 [4],[5]  
Biopharma (operating segment) | Dupixent [Member]        
Disclosure of geographical areas [line items]        
Net sales 13,072 10,715 [3] 8,292 [3]  
Biopharma (operating segment) | Aubagio [Member]        
Disclosure of geographical areas [line items]        
Net sales   379 955 [3] € 2,029 [3]
Biopharma (operating segment) | Cerezyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     686  
Biopharma (operating segment) | Fabrazyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     990  
Biopharma (operating segment) | Myozyme Or Lumizyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     782  
Biopharma (operating segment) | Lovenox [Member]        
Disclosure of geographical areas [line items]        
Net sales     1,122  
Biopharma (operating segment) | Industrial Sales [Member]        
Disclosure of geographical areas [line items]        
Net sales 523 551 [3] 608 [3]  
Biopharma (operating segment) | Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales   7,477    
Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 2,741 2,766 [3] 2,860 [3]  
Biopharma (operating segment) | Influenza Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 2,555 2,669 [3] 2,977 [3]  
Biopharma (operating segment) | RSV Vaccines (Beyfortus)        
Disclosure of geographical areas [line items]        
Net sales 1,686 547 [3] 0 [3]  
Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines        
Disclosure of geographical areas [line items]        
Net sales 1,316 1,266 [3] 1,309 [3]  
Biopharma (operating segment) | Nexviazyme        
Disclosure of geographical areas [line items]        
Net sales 667 425 [3] 196 [3]  
Biopharma (operating segment) | Sarclisa        
Disclosure of geographical areas [line items]        
Net sales 471 381 [3] 294 [3]  
Biopharma (operating segment) | ALTUVIIIO        
Disclosure of geographical areas [line items]        
Net sales 682 159 [3] 0 [3]  
Biopharma (operating segment) | Rezurock        
Disclosure of geographical areas [line items]        
Net sales 470 310 [3] 207 [3]  
Biopharma (operating segment) | Cablivi        
Disclosure of geographical areas [line items]        
Net sales 249 227 [3] 211 [3]  
Biopharma (operating segment) | Xenpozyme        
Disclosure of geographical areas [line items]        
Net sales 151 91 [3] 21 [3]  
Biopharma (operating segment) | Enjaymo        
Disclosure of geographical areas [line items]        
Net sales 105 72 [3] 22 [3]  
Biopharma (operating segment) | Tzield        
Disclosure of geographical areas [line items]        
Net sales 54 25 [3] 0 [3]  
Libtayo Segment        
Disclosure of operating segments [line items]        
Business operating income     952  
Business Operating Income, Net of Tax     706  
Europe        
Disclosure of geographical areas [line items]        
Net sales 9,027 8,816 [6] 8,490 [7]  
Europe | Biopharma (operating segment)        
Disclosure of geographical areas [line items]        
Net sales 9,027 8,816 8,490  
Europe | Biopharma (operating segment) | Dupixent [Member]        
Disclosure of geographical areas [line items]        
Net sales 1,618 1,224 940  
Europe | Biopharma (operating segment) | Aubagio [Member]        
Disclosure of geographical areas [line items]        
Net sales   152 437 511
Europe | Biopharma (operating segment) | Industrial Sales [Member]        
Disclosure of geographical areas [line items]        
Net sales 520 528 580  
Europe | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 497 477 479  
Europe | Biopharma (operating segment) | Influenza Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 640 694 681  
Europe | Biopharma (operating segment) | RSV Vaccines (Beyfortus)        
Disclosure of geographical areas [line items]        
Net sales 440 140 0  
Europe | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines        
Disclosure of geographical areas [line items]        
Net sales 204 157 112  
Europe | Biopharma (operating segment) | Nexviazyme        
Disclosure of geographical areas [line items]        
Net sales 201 100 17  
Europe | Biopharma (operating segment) | Sarclisa        
Disclosure of geographical areas [line items]        
Net sales 134 111 88  
Europe | Biopharma (operating segment) | ALTUVIIIO        
Disclosure of geographical areas [line items]        
Net sales 0 0 0  
Europe | Biopharma (operating segment) | Rezurock        
Disclosure of geographical areas [line items]        
Net sales 28 5 1  
Europe | Biopharma (operating segment) | Cablivi        
Disclosure of geographical areas [line items]        
Net sales 93 98 94  
Europe | Biopharma (operating segment) | Xenpozyme        
Disclosure of geographical areas [line items]        
Net sales 46 31 15  
Europe | Biopharma (operating segment) | Enjaymo        
Disclosure of geographical areas [line items]        
Net sales 17 6 0  
Europe | Biopharma (operating segment) | Tzield        
Disclosure of geographical areas [line items]        
Net sales 1 0 0  
United States        
Disclosure of geographical areas [line items]        
Net sales 19,986 17,262 [6] 16,986 [7]  
United States | Biopharma (operating segment)        
Disclosure of geographical areas [line items]        
Net sales 19,986 17,262 16,986  
United States | Biopharma (operating segment) | Dupixent [Member]        
Disclosure of geographical areas [line items]        
Net sales 9,544 8,145 6,346  
United States | Biopharma (operating segment) | Aubagio [Member]        
Disclosure of geographical areas [line items]        
Net sales   187 460 1,420
United States | Biopharma (operating segment) | Fabrazyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     503  
United States | Biopharma (operating segment) | Industrial Sales [Member]        
Disclosure of geographical areas [line items]        
Net sales 1 4 17  
United States | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 679 721 787  
United States | Biopharma (operating segment) | Influenza Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 1,433 1,406 1,737  
United States | Biopharma (operating segment) | RSV Vaccines (Beyfortus)        
Disclosure of geographical areas [line items]        
Net sales 1,068 407 0  
United States | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines        
Disclosure of geographical areas [line items]        
Net sales 736 730 767  
United States | Biopharma (operating segment) | Nexviazyme        
Disclosure of geographical areas [line items]        
Net sales 361 272 158  
United States | Biopharma (operating segment) | Sarclisa        
Disclosure of geographical areas [line items]        
Net sales 200 165 127  
United States | Biopharma (operating segment) | ALTUVIIIO        
Disclosure of geographical areas [line items]        
Net sales 617 155 0  
United States | Biopharma (operating segment) | Rezurock        
Disclosure of geographical areas [line items]        
Net sales 425 303 206  
United States | Biopharma (operating segment) | Cablivi        
Disclosure of geographical areas [line items]        
Net sales 136 112 110  
United States | Biopharma (operating segment) | Xenpozyme        
Disclosure of geographical areas [line items]        
Net sales 81 52 5  
United States | Biopharma (operating segment) | Enjaymo        
Disclosure of geographical areas [line items]        
Net sales 58 42 17  
United States | Biopharma (operating segment) | Tzield        
Disclosure of geographical areas [line items]        
Net sales 52 25 0  
Other Countries In Segment Results [Member] | Biopharma (operating segment)        
Disclosure of geographical areas [line items]        
Net sales 12,068 11,739 12,175  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Dupixent [Member]        
Disclosure of geographical areas [line items]        
Net sales 1,910 1,346 1,006  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Aubagio [Member]        
Disclosure of geographical areas [line items]        
Net sales   40 58 € 98
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cerezyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     268  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Fabrazyme [Member]        
Disclosure of geographical areas [line items]        
Net sales     246  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Industrial Sales [Member]        
Disclosure of geographical areas [line items]        
Net sales 2 19 11  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 1,565 1,568 1,594  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Influenza Vaccines [Member]        
Disclosure of geographical areas [line items]        
Net sales 482 569 559  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | RSV Vaccines (Beyfortus)        
Disclosure of geographical areas [line items]        
Net sales 178 0 0  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines        
Disclosure of geographical areas [line items]        
Net sales 376 379 430  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Nexviazyme        
Disclosure of geographical areas [line items]        
Net sales 105 53 21  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Sarclisa        
Disclosure of geographical areas [line items]        
Net sales 137 105 79  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | ALTUVIIIO        
Disclosure of geographical areas [line items]        
Net sales 65 4 0  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Rezurock        
Disclosure of geographical areas [line items]        
Net sales 17 2 0  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cablivi        
Disclosure of geographical areas [line items]        
Net sales 20 17 7  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Xenpozyme        
Disclosure of geographical areas [line items]        
Net sales 24 8 1  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Enjaymo        
Disclosure of geographical areas [line items]        
Net sales 30 24 5  
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Tzield        
Disclosure of geographical areas [line items]        
Net sales € 1 € 0 € 0  
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo
transaction (€706 million net of tax).
[6] (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.